. 2021 Jan 12;16(1):e0245112. doi: 10.1371/journal.pone.0245112

Table 2. Characteristics of the studies presented in the articles included.

Source	Type of study	Multi- / Monocentric	Country	Number of patients	Medical characteristics	Intervention	Type of intervention	Follow-up duration	Comparator	Primary endpoint
Reimer (2008)	RCT	Mono	Germany	60	Patients with type 2 diabetes without any experience with insulin injection devices	Prefilled insulin pen	MEDICAL DEVICE	<1 day	Cartridge insulin pen	Instruction time
Reimer (2008)	RCT	Mono	Germany	60		Prefilled insulin pen	Ease of use	<1 day	Cartridge insulin pen	Instruction time
Koek (2009)	RCT	Multi	Netherlands	200	Patients with mild-to-severe psoriasis	Home ultraviolet B phototherapy	CARE	52 weeks	Outpatient ultraviolet B phototherapy	Clinical
Koek (2009)	RCT	Multi	Netherlands	200	Patients with mild-to-severe psoriasis	Home ultraviolet B phototherapy	Process	52 weeks	Outpatient ultraviolet B phototherapy	Clinical
Oude Elberink (2009)	nRCT	Mono	Netherlands	55	Patients with yellow jacket sting allergy (dermal reactions only)	Immunotherapy (VIT) + Epipen	DRUG	52 weeks	Epipen only	Quality of life (PROM)
Oude Elberink (2009)	nRCT	Mono	Netherlands	55		Immunotherapy (VIT) + Epipen	Strategy	52 weeks	Epipen only	Quality of life (PROM)
Ishii (2011)	UBA	Multi	Japan	346	Insulin-naïve patients with type 2 diabetes initiating treatment with BIAsp	BIAsp treatment	DRUG	26 weeks	-	Treatment satisfaction, including BoT (PROM)
Ishii (2011)	UBA	Multi	Japan	346		BIAsp treatment	Strategy	26 weeks	-	Treatment satisfaction, including BoT (PROM)
Martin (2013)	RCT	Multi	-	586	Patients with type 2 diabetes, poorly controlled with insulin glargine, detemir or NPH	Albiglutide once a week	DRUG	52 weeks	Insulin lispro 3 times/day	Biological
Martin (2013)	RCT	Multi	-	586		Albiglutide once a week	Dose frequency	52 weeks	Insulin lispro 3 times/day	Biological
Bilton (2014)	RCT	Multi	17 countries (Europe and Canada)	302	Patients with cystic fibrosis and chronic infection due to P. aeruginosa	Antibiotics (liposomal amikacin): 1 inhalation/day	DRUG	26 weeks	Antibiotics (tobramycin): 2 inhalations/day	Clinical
Bilton (2014)	RCT	Multi	17 countries (Europe and Canada)	302		Antibiotics (liposomal amikacin): 1 inhalation/day	Dose frequency	26 weeks	Antibiotics (tobramycin): 2 inhalations/day	Clinical
Quittner (2015)	RCT	Multi	USA	152	Patients with cystic fibrosis and the G551D-CFTR mutation	Ivacaftor	DRUG	52 weeks	Placebo	Clinical
Quittner (2015)	RCT	Multi	USA	152	Patients with cystic fibrosis and the G551D-CFTR mutation	Ivacaftor	Strategy	52 weeks	Placebo	Clinical
Garg (2016)	RCT	Multi	USA	242	Diabetic patients with a previous experience with vial/syringe treatment, and without experience with insulin pen	New prefilled insulin pen	MEDICAL DEVICE	24 weeks	Original prefilled insulin pen	Preference for a device
Garg (2016)	RCT	Multi	USA	242		New prefilled insulin pen	Ease of use	24 weeks	Original prefilled insulin pen	Preference for a device
Kabul (2016)	RCT	Multi	USA	325	Patients with type 2 diabetes, switching from U-100 insulin to U-500 insulin	Insulin U-500 twice a day	DRUG	24 weeks	Insulin U-500 3 times/day	Health-related Quality of Life, including BoT (PROM)
Kabul (2016)	RCT	Multi	USA	325		Insulin U-500 twice a day	Dose frequency	24 weeks	Insulin U-100 more often
Salisbury (2018)	RCT	Multi	England, Scotland	1,546	Patients with 3 or more long-term conditions, followed by a general practitioner	3-D approach (patient-centred care) implemented by general practitioners, pharmacists, nurses	CARE	65 weeks	Usual care by general practitioners, pharmacists, nurses	Health-related Quality of Life, not including BoT (PROM)
Salisbury (2018)	RCT	Multi	England, Scotland	1,546			Process	65 weeks	Usual care by general practitioners, pharmacists, nurses	Health-related Quality of Life, not including BoT (PROM)
Ishii (2019)	RCT	Multi	Japan	218	Patients with type 2 diabetes, previously managed with diet and exercise only, requiring a DPP-4 inhibitor	Trelagliptin once a week	DRUG	12 weeks	DDP-4 inhibitor once or twice a day	Diabetes Therapy-Related Quality of Life (DTR QOL), including BoT (PROM)
Ishii (2019)	RCT	Multi	Japan	218		Trelagliptin once a week	Dose frequency	12 weeks	DDP-4 inhibitor once or twice a day

RCT = Randomised Controlled Trial, UBA = Uncontrolled Before-and-After study, BoT = Burden of Treatment, NPH = Neutral Protamine Hagedorn, PROM = Patient-Reported Outcome Measures, VIT = Venom-Specific Immunotherapy, BIAsp = Biphasic Insulin Aspart, DPP-4 = Dipeptidyl Peptidase-4.